Cerebrospinal fluid insulin-like growth factor (IGF-1) and insulin-like growth factor binding protein (IGFBP-2) in children with acute lymphoblastic leukemia

Pediatric Blood and Cancer

Volumn 43, Issue 2, 2004, Pages 110-114

  Riikonen, Raili ^a,d   Vettenranta, Kim ^b   Riikonen, Pekka ^a   Turpeinen, U ^c   Saarinen Pihkala, Ulla M ^b  

^a UNIVERSITY OF HELSINKI AND HELSINKI UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

ALL; CSF; Insulin like growth factors

Indexed keywords

ASPARAGINASE; CONNECTIVE TISSUE GROWTH FACTOR; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; SOMATOMEDIN C; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DRUG MECHANISM; HUMAN; INFANT; INSULIN LIKE ACTIVITY; LONGITUDINAL STUDY; MYELINATION; NERVE FIBER GROWTH; NERVE FUNCTION; NEUROLOGIC DISEASE; POLYNEUROPATHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN CEREBROSPINAL FLUID LEVEL; RADIOIMMUNOASSAY; STATISTICAL ANALYSIS;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASE-CONTROL STUDIES; CENTRAL NERVOUS SYSTEM DISEASES; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FINLAND; FOLLOW-UP STUDIES; HUMANS; INFANT; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INSULIN-LIKE GROWTH FACTOR I; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; PILOT PROJECTS; STATISTICS, NONPARAMETRIC;

EID: 3042748342     PISSN: 15455009     EISSN: None     Source Type: Journal    
DOI: 10.1002/pbc.20072     Document Type: Article

References (29)

1. Beck K, Bowell-Braxton L, Widmer H-R, et al. IGF-1 gene disruption results in reduced brain size, CNS hypomyelination, and loss of hippocampal granule and striatal paralbumin-containing neurons. Neuron 1995;14:717-730.
2. Barres B. Cell death and control of cell survival in the oligodendrocyte lineage. Cell 1992;70:31-46.
3. D'Mello S, Borodezt K, Soltoff S. Insulin-like growth factor and potassium depolarization maintain neuronal survival by distinct pathways: Possible involvement of P13-kinase in IGF-1 signalling. J Neurosci 1997;17:1548-1560.
4. Mozell R, McMorris F. Insulin-like growth factor I stimulates oligodendrocyte development and myelination in rat brain aggregate culture. J Neurosci Res 1991;30:382-390.
5. Ye P, Carson J, D'Ercole A. In vivo actions of insulin-like growth factor-1 (IGF-1) on brain myelination: Studies of IGF-1 and binding protein-1 (IGFBP-1) in transgenic mice. J Neurosci 1995;15:7344-7356.
6. Leventhal P, Russel J, Feldman E. IGFs and the Nervous System. In: Rosenfeld RG, Roberts CT, Jr., editors. The IGF system: Molecular biology, physiology, and clinical applications. Totowa, NJ: Humana Press, Inc; 1999. pp 425-444.
7. Sara V, Carlsson-Skwirut C. Insulin-like factors on the central nervous system: Biosynthesis and biological role. In: Sara V, Hall K, Low H, editors. Growth factors: From genes to clinical application. New York: Raven Press; 1990. pp 179-191.
8. Bach M, Shen-Orr Z, Lowe W, et al. Insulin-like factor 1 mRNA levels are developmentally regulated in specific regions of the rat brain. Mol Brain Res 1991;10:43-48.
9. Riikonen R, Vanhanen S-L, Tyynelä J, et al. CSF insulin-like growth factor-1 in infantile neuronal ceroid lipofuscinosis. Neurology 2000;54:1828-1832.
10. Riikonen R, Somer M, Turpeinen U. Low-insulin-like growth factor (IGF-1) in the cerebrospinal fluid of children with progressive encephalopathy, hypsarrhythmia, optic atrophy (PEHO) syndrome, and cerebellar degeneration. Epilepsia 1999;40:1642-1648.
11. Vanhala R, Turpeinen U, Riikonen R. Low levels of insulin-like growth factor in cerebrospinal fluid in children with autism. J Child Neurol 2001;43:614-616.
12. Gustafsson G, Schmegelow K, Forestier E, et al. On behalf of NOPHO. Improving outcome through two decades in childhood ALL in the Nordic countries: The impact of high-dose methotrexate in the reduction of CNS irradiation. Leukemia 2000;4:2267-2275.
13. Han V. Is the central nervous system a target for growth hormone and insulin-like growth factors? Acta Ped Suppl 1995;411:3-6.
14. Carson M, Behringer R, Brinster R, et al. Insulin-like growth factor I increases brain growth and central nervous system myelination in transgenic mice. Neuron 1993;10:729-740.
15. Bach M, Shen-Orr Z, Lowe W, et al. Insulin-like growth factor I mRNA levels are developmentally regulated in specific regions of the brain. Mol Brain Res 1991;10:43-48.
16. Adamo M, Werner H, Farnsworth W, et al. Dexamethasone reduces steady state insulin-like growth factor I messenger ribonucleic acid levels in rat neuronal and glial cells in primary culture. Endocrinology 1998;123:2565-2570.
17. Balis F, Holcenberg J, Bleyer W. Clinical pharmacokinetics of commonly used anticancer drugs. Clin Pharmacokinet 1981;8:202-232.
18. Sahenk Z, Brady ST, Mendell J. Studies on the pathogenesis of vincristine-induced neuropathy. Muscle Nerv 1987;10:80-84.
19. Gavrilovic J, Brennan A, Mirsky R, et al. Fibroblast growth factor and insulin-like growth factors combine to promote survival of rat Schwann cell precursors without induction of DNA synthesis. Eur J Neurosci 1995;7:77-85.
20. Dore S, Kar S, Quirion R. Rediscovering an old friend, IGF-1: Potential use in the treatment of neurodegenerative diseases. Trends Neurosci 1997;20:326-331.
21. Lai E, Felice K, Festoff B, et al. Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. Neurology 1997;49:1621-1630.
22. Apfel S, Kessler J, Adornato B, et al. the NGF Study Group. Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. Neurology 1998;51:695-702.
23. Ishii D. Implication of insulin-like growth factors in the pathogenesis of diabetic neuropathy. Brain Res Brain Res Rev 1995;20:47-67.
24. Zhuang H, Snyder C, Pu S, et al. Insulin-like growth factors reverse or arrest diabetic neuropathy: Effects on hyperalgesia and impaired nerve regeneration in rats. Exp Neurol 1996;140:198-205.
25. Apfel S, Arezzo J, Lewis M, et al. The use of IGF-1 in the prevention of vincristine neuropathy in mice. Ann NY Acad Sci 1993;692:243-245.
26. Isley W, Underwood L, Clemmons D. Dietary components that regulate serum somatomedin-C concentrations in humans. J Clin Invest 1983;71:175-182.
27. Koskelo E-K, Saarinen U, Siimes A. Skeletal muscle wasting and protein-energy malnutrition in children with newly diagnosed acute leukaemia. Cancer 1990;66:373-376.
28. Lee W, Michels K, Bondy C. Localization of insulin-like growth factor binding protein-2 messenger RNA during postnatal brain development: Correlation with insulin-like growth factor I and II. Neuroscience 1993;53:251-256.
29. Heinze E, Böker M, Blum W, et al. GH, IGF-1, IGFBP-3 and IGFBP-2 in cerebrospinal fluid of infants, during puberty and in adults. Endocrinol Diab 1998;106:197-202.